Publication | Open Access

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Substance Use DisordersOral NaltrexoneSubstance AbuseOpioid EpidemicHarm ReductionSubstance UseHealth PolicySubstance Use TreatmentAddictionHealth InsuranceAddiction MedicineBuprenorphine UtilizationDrug TreatmentMedicineUnited StatesHealth Services ResearchOpioid Use DisorderHealth Sciences